Unicycive Therapeutics (UNCY) Liabilities and Shareholders Equity (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $64.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 130.46% year-over-year to $64.4 million; the trailing twelve-month figure through Mar 2026 stood at $194.1 million (up 35.87% YoY), and the FY2025 full-year result was $49.1 million, up 55.16% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $64.4 million, up from $49.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $64.4 million in Q1 2026 and bottomed at $2.8 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $27.9 million (2025), against an average of $30.3 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 1303.72% in 2022, while the deepest fall reached 84.97% in 2022.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.8 million in 2022, then surged by 403.58% to $14.2 million in 2023, then soared by 123.16% to $31.7 million in 2024, then soared by 55.16% to $49.1 million in 2025, then jumped by 31.08% to $64.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $64.4 million (Q1 2026), $49.1 million (Q4 2025), and $50.6 million (Q3 2025), per Business Quant data.

Peer Comparison